The current analysis reexamines the relationship between supplemental vitamin E and all-cause mortality. All randomized, controlled trials testing the treatment effect of vitamin E supplementation in adults for at least one year were sought. MEDLINE, the Cochrane Library, and Biological Abstracts databases were searched using the terms "vitamin E," "alpha-tocopherol," "antioxidants," "clinical trial," and "controlled trial" for studies published through April 2010; results were limited to English, German, or Spanish language articles. Studies were also obtained through reference mining. All randomized controlled trials using vitamin E, with a supplementation period of at least one year, to prevent or treat disease in adults were identified and abstracted independently by two raters. Mortality data from trials with a supplementation period of at least one year were pooled. The selected trials (n = 57) were published between 1988 and 2009. Sample sizes range from 28 to 39,876 (median = 423), yielding 246,371 subjects and 29,295 all-cause deaths. Duration of supplementation for the 57 trials range from one to 10.1 years (median = 2.6 years). A random effects meta-analysis produce an overall risk ratio of 1.00 (95% confidence interval: 0.98, 1.02); additional analyses suggest no relationship between dose and risk of mortality. Based on the present meta-analysis, supplementation with vitamin E appears to have no effect on all-cause mortality at doses up to 5,500 IU/d.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030744PMC
http://dx.doi.org/10.2174/1874609811104020158DOI Listing

Publication Analysis

Top Keywords

all-cause mortality
12
vitamin all-cause
8
randomized controlled
8
controlled trials
8
vitamin supplementation
8
supplementation period
8
period year
8
vitamin
5
mortality
5
trials
5

Similar Publications

Overall and late mortality among 24 459 survivors of adolescent and young adult cancer in Alberta, Canada: a population-based cohort study.

Lancet Public Health

January 2025

Department of Oncology, University of Calgary, Calgary, AB, Canada; Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada; Department of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, Alberta Health Services, Arthur Child Comprehensive Cancer Centre, Calgary, AB, Canada. Electronic address:

Background: Adolescent and young adult (AYA) cancer survivors are at an increased risk of premature mortality due to their cancer and its treatment. Herein, we aimed to quantify the excess risks of mortality among AYA cancer survivors and identify target populations for intervention.

Methods: The Alberta AYA Cancer Survivor Study is a retrospective, population-based cohort of individuals diagnosed with a first primary neoplasm at age 15-39 years in Alberta, Canada, between 1983 and 2017.

View Article and Find Full Text PDF

Background: - Little is known about mitral transcatheter edge-to-edge repair (TEER) performed outside of usual working hours. We aimed to explore the prevalence, correlates, and outcomes of mitral TEER initiated off-hours, i.e.

View Article and Find Full Text PDF

Diminished salivary cortisol response to mental stress predict all-cause mortality in general population.

J Psychosom Res

December 2024

The Second Clinical Medical College, Jinan University, Shenzhen 518020, China; Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China; School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China. Electronic address:

Objectives: To characterize individuals with a diminished salivary cortisol response to mental stress, assess its association with all-cause mortality, and quantify the mediating effects of the most relevant and modifiable factors to identify potential target for prevention.

Methods: Data from MIDUS II study with a 16-year follow-up, were used to categorize 1129 participants as responders or non-responders based on the existence of increase in salivary cortisol under mental stress. LASSO-logistics analysis identified the most relevant factors.

View Article and Find Full Text PDF

Predicting the likelihood of readmission in patients with ischemic stroke: An explainable machine learning approach using common data model data.

Int J Med Inform

December 2024

Department of Health Policy and Management, School of Medicine, Kangwon National University, 510 School of Medicine Building #1 (N414), 1, Kangwondaehak-gil, Chuncheon-si, Gangwon-do 24341, Republic of Korea; Department of Preventive Medicine, Kangwon National University Hospital, 156 Baengnyeong-ro, Chuncheon-si, Gangwon-do 24289, Republic of Korea; Team of Public Medical Policy Development, Gangwon State Research Institute for People's Health, 880 Baksa-ro, Seo-myeon, Chuncheon-si, Gangwon-do 24461, Republic of Korea. Electronic address:

Background: Ischemic stroke affects 15 million people worldwide, causing five million deaths annually. Despite declining mortality rates, stroke incidence and readmission risks remain high, highlighting the need for preventing readmission to improve the quality of life of survivors. This study developed a machine-learning model to predict 90-day stroke readmission using electronic medical records converted to the common data model (CDM) from the Regional Accountable Care Hospital in Gangwon state in South Korea.

View Article and Find Full Text PDF

Impact of adjuvant trastuzumab therapy and its discontinuation on cardiac function and mortality in patients with early-stage breast cancer: An analysis based on the Japanese Receipt Claim Database.

Breast

December 2024

Department of Clinical Research and Management, Graduate School of Medicine, University of Ryukyus, Japan; Department of Clinical Pharmacology, Faculty of Medicine, University of the Ryukyus, Japan. Electronic address:

Standard trastuzumab therapy can reduce the risk of early recurrence of HER2-positive breast cancer. However, trastuzumab-induced cardiac dysfunction may force the discontinuation of adjuvant trastuzumab therapy. Incidentally, there are still unclear whether or not trastuzumab treatment should be continued in the setting of reduced cardiac function.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!